Clinical trial NCT02899000: A Treatment for Severe Inflammatory Acne Subjects
Official title: Efficacy and Safety of Adapalene 0.3%/Benzoyl Peroxide 2.5% Gel Plus Doxycycline in Severe Inflammatory Acne (Non-Nodulocystic) Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Acne Vulgaris
Lead sponsor: Galderma R&D
Sponsor class: INDUSTRY
First posted: 2016-09-13
Enrollment: 186
Sex: ALL
Minimum age (years): 12
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Demonstrate that a daily treatment regimen of adapalene 0.3%/benzoyl peroxide 2.5% gel + oral Doxycycline 200 mg is effective and safe in severe inflammatory acne with 3 or fewer nodules or cysts (non-nodulocystic) during a 12-week treatment period.

Detailed description: This Phase 4, 12-week, single-arm, open-label, multi-center investigational efficacy and safety study was conducted in subjects with severe inflammatory acne. Subjects who met the inclusion criteria and none of the exclusion criteria at the Screening visit returned to the clinic for baseline measures (Week 0) and to start treatment, which continued for up to 12 weeks.

Treatment consisted of 2 investigational study drugs:

* A/BPO 0.3%/2.5% gel applied to dry skin as directed by study staff once daily for 12 weeks, at night after washing.
* Doxycycline hyclate 200 mg: each subject was to take 2 50-mg tablets of doxycycline hyclate in the morning and 2 at night, for a total of 4 tablets (a total of 200 mg) daily for 12 weeks.

Eligibility criteria: Key Inclusion Criteria:

1. Male or female subjects, 12 years of age or older at Screening visit.
2. Subjects with a clinical diagnosis of severe inflammatory acne (IGA score of 4).
3. Subjects with 4 or fewer nodules or cysts \> 1 cm in diameter on the face.
4. Subjects 18 years of age or older must read and sign the Informed Consent Form, which includes Photography Consent and HIPAA authorization, prior to any participation in the study. Consent will be obtained prior to any study-related procedures. Subjects under the age of 18 years must sign an Assent to Participate Form to participate in the study and must have one parent or guardian read and sign the Informed Consent Form prior to any study-related procedure. (The parent or guardian is not required to attend the following visits unless requested.)

Key Exclusion Criteria:

1. Subjects with nodulocystic or conglobate acne, acne fulminans, or secondary acne (chloracne, drug-induced acne, etc.).
2. Subjects with 5 or more acne nodules or cysts \> 1 cm in diameter on the face at Screening and Baseline visits.
3. Female subjects who are pregnant, nursing, or planning a pregnancy during the study.
4. Subjects who have used any systemic therapy directed at improving acne, including antibiotics, within 30 days prior to Baseline visit.
5. Subjects who are at risk in terms of precautions, warnings, and contraindications for the investigational study drugs (see Appendix 14.1 for package inserts for adapalene 0.3%/benzoyl peroxide 2.5% gel and doxycycline hyclate Tablets).
6. Subjects with any other condition or circumstance which, in the Investigator's opinion, may put the subject at risk (e.g., a history of significant renal disease with impairment of renal function), confound the study results, or interfere with the subject's participation in the study.
7. Sponsor and study site staff, relatives of staff members, or other individuals who would have access to the clinical study protocol.

Primary outcomes:
measure: Change in Number of Inflammatory Lesions
timeFrame: Week 12
Secondary outcomes:
measure: Number and Percent of Subjects With IGA Success
timeFrame: Weeks 4, 8, and 12
measure: Percent Change From Baseline in Total Lesion Count
timeFrame: Weeks 4, 8, and 12
measure: Change From Baseline in Total Lesion Count
timeFrame: Weeks 4, 8, and 12
measure: Percent Change From Baseline in Inflammatory Lesion Count
timeFrame: Weeks 4, 8, and 12
measure: Change From Baseline in Inflammatory Lesion Count
timeFrame: Weeks 4, 8, and 12
measure: Percent Change From Baseline in Non-Inflammatory Lesion Count
timeFrame: Weeks 4, 8, and 12
measure: Change From Baseline in Non-Inflammatory Lesion Count
timeFrame: Weeks 4, 8, and 12
measure: Investigator's Evaluation: Number of Subjects Not Considered to be Oral Isotretinoin Candidates
timeFrame: Weeks 0, 4, 8, and 12
measure: Subject Assessment of Acne Improvement
timeFrame: Week 12
measure: Number and Percent of Adverse Events
timeFrame: Week 12
Other outcomes:
Locations:
city: Fort Worth
country: United States
facility: Galderma Laboratories, LP
state: Texas
Study officials:
References:
citation: Del Rosso JQ, Stein Gold L, Johnson SM, Rueda MJ, Baldwin H, Lain EL, Landis M, Rendon M, Tanghetti E, Weiss J. Efficacy and Safety of Adapalene 0.3%/Benzoyl Peroxide 2.5% Gel Plus Oral Doxycycline in Subjects With Severe Inflammatory Acne Who Are Candidates for Oral Isotretinoin. J Drugs Dermatol. 2018 Mar 1;17(3):264-273.